Belimumab in SLE

You likely can't join if

•  Patients who are not able to give informed consent.  Pregnancy  Severe renal impairment (eGFR <30ml/min/1.73m2)  Active nephritis  Present or previous treatment with any cell depleting therapies, including anti-B-cell therapy or other investigational agents (e.g., abetimus sodium, anti CD40L antibody, BG9588/ IDEC 131). Investigational agent applies to any drug not approved for sale in the country in which it is being used.  90 days prior to belimumab: • Intravenous cyclophosphamide  30 Days Prior to belimumab (or 5 half-lives, whichever is greater) • Any non-biologic investigational agent. Investigational agent applies to any drug not approved for sale in the country in which it is being use  Live vaccines within 30 days prior to baseline or concurrently with belimumab  Presence of any other disease for which study subjects need chronic or intermittent immunosuppressive therapy (e.g. prednisolon for COPD).  History of infection: • Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria) • Hospitalization for treatment of infection within 60 days of Day 0. • Use of parenteral (IV or IM) antibiotics (anti-bacterial, antiviral, anti-fungal, or anti-parasitic agents) within 60 days of Day 0  History of malignancies neoplasm within the last 5 years except basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years  Have any intercurrent significant medical or psychiatric illness that the investigator considers would make the candidate unsuitable for the study, including evidence of serious suicide risk including any history of suicidal behaviour in the last 6 months and/or any suicidal ideation in the last 2 months or who in the investigator's judgment, poses a significant suicide risk  Have a history of a primary immunodeficiency, including significant IgG deficiency (IgG level < 400 mg/dL) or IgA deficiency (IgA level < 10 mg/dL)  Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 365 days prior to Day 0  Have a historically positive HIV test or test positive at screening for HIV  Hepatitis status: • Serologic evidence of current or past Hepatitis B (HB) infection based on the results of testing for HBsAg and HBcAb as follows: patients positive for HBsAg or HBcAb are excluded • Positive test for Hepatitis C antibody  Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies  Have any other clinically significant abnormal laboratory value in the opinion of the investigator